In this line, the ATHENA study analyzed two cohorts of patients with T2D, namely patients at high cardiovascular risk (THEMIS-like cohort; n = 56,040) and patients at high cardiovascular risk or taking P2Y12 inhibitors (CAD-T2D cohort; n = 69,790). The gene discussed is P2RY12; the disease is coronary artery disorder.